Compare Alcon AG (ALC) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Hut 8 Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Hut 8 Corp trades at $105.99 (market cap $10.89B). The key difference: Alcon AG is far larger — about 3× Hut 8 Corp's market cap, and Alcon AG pays a 0.54% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| ALC | HUT | |
|---|---|---|
Market Cap | $32.69B | $10.89B |
Sector | Health | Technology |
52-Week High | $92.22 | $133.02 |
52-Week Low | $62.02 | $19.45 |
Enterprise Value | $36.28B | $11.15B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
HUT trades at $103.78, up 6.84% today, but faces bearish technical signals with resistance at $108. The company shows strong analyst support (93.75% buy ratings) with a $129.44 consensus target, yet fundamentals reveal challenges: negative net income margin of -109.77% in 2025 and operating cash flow of -$139.23M. Recent news highlights Hut 8's pivot to AI infrastructure, closing $4.25B in project financing for data centers, signaling strategic growth amid profitability concerns.
Outlook: High growth potential from AI/data center expansion, but elevated execution risks and persistent losses warrant caution. Near-term price movement may hinge on Q2 2026 earnings (expected EPS -$0.32) and Bitcoin market volatility. Risks include competitive pressures and reliance on financing for cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
